Inhibition Of Renal Glucose Reabsorption

Name: INTERSTELLAR BLENDS
Address: 134 Vintage Park Blvd Ste A #331, Houston, TX, 77070, US
Telephone: +1-737-333-6345

Inhibition of Renal Glucose Reabsorption: a novel strategy for achieving Glucose control in type 2 diabetes mellitus
Inhibition of Renal Glucose Reabsorption as a novel treatment for diabetes patients
Renal Glucose Reabsorption inhibitors to treat diabetes
Characterization of Renal Glucose Reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes
Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in Renal Glucose Reabsorption in humans
Development of the Renal Glucose Reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2
Effect of Lepidium sativum L. on Renal Glucose Reabsorption and urinary TGF‐β1 levels in diabetic rats
Selective SGLT2 Inhibition by tofogliflozin reduces Renal Glucose Reabsorption under hyperglycemic but not under hypo-or euglycemic conditions in rats
Antihyperglycemic effect of T-1095 via Inhibition of Renal Na+-Glucose cotransporters in streptozotocin-induced diabetic rats
Renal Glucose transporters: novel targets for hyperglycemia management
Role of the kidney in normal Glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
Renal, metabolic and cardiovascular considerations of SGLT2 Inhibition
Sodium-Glucose cotransporter-2 Inhibition and the glomerulus: a review
From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
Type 2 sodium-Glucose cotransporter (SGLT2) inhibitors: from familial Renal glucosuria to the treatment of type 2 diabetes mellitus
Inhibition of the intestinal sodium‐coupled Glucose transporter 1 (SGLT1) by extracts and polyphenols from apple reduces postprandial blood Glucose levels in mice …
Glucose metabolism in the kidney: neurohormonal activation and heart failure development
The role of the kidney and sodium-Glucose cotransporter-2 Inhibition in diabetes management
Effect of phlorhizin on Renal Glucose and phosphate transport in the dog
Exploring newer target sodium Glucose transporter 2 for the treatment of diabetes mellitus
Glucose control by the kidney: an emerging target in diabetes
Targeting Renal Glucose Reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin
Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus
Role of the Kidney in Type 2 Diabetes and Mechanism of Action of Sodium Glucose Cotransporter-2 Inhibitors
Novel Indole-N-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes
Dapagliflozin: a sodium Glucose cotransporter 2 inhibitor in development for type 2 diabetes
SGLT2 Inhibition in diabetes mellitus: rationale and clinical prospects
Effect of sodium-Glucose cotransport Inhibition on polycystic kidney disease progression in PCK rats
Sodium Glucose co-transporter 2 (SGLT2) inhibitor
Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary Glucose excretion in healthy subjects
The role of the kidneys in Glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium Glucose co-transporter 2 …
SGLT2 Inhibition—a novel strategy for diabetes treatment
Tofogliflozin, a potent and highly specific sodium/Glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice
SGLT2 inhibitors: molecular design and potential differences in effect
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin–nicotinamide-induced mildly diabetic mice
Sodium‐Glucose co‐transporter (SGLT) and Glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects
Does urea Reabsorption occur via the Glucose pathway in the kidney of the freshwater rainbow trout?
Model analysis of effect of canagliflozin (Invokana), a sodium–Glucose cotransporter 2 inhibitor, to alter plasma 1, 5-anhydroglucitol
Modified cycloartanes with improved inhibitory effect on SGLT-mediated Glucose uptake in human Renal proximal tubular cells
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
Phlorizin-like effect of Fraxinus excelsior in normal and diabetic rats
Dapagliflozin, a novel SGLT2 inhibitor, induces dose‐dependent glucosuria in healthy subjects
Hypoglycaemic activity of Retama raetam in rats
Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-Glucose co-transporter type 2
Role of the kidney in Glucose homeostasis: implications for SGLT-2 Inhibition in the treatment of type 2 diabetes mellitus
Sodium-Glucose co-transport inhibitors
Dapagliflozin: a selective sodium-Glucose co-transporter-2 inhibitor in type 2 diabetes.
In vitro–in vivo correlation of the Inhibition potency of sodium-Glucose cotransporter inhibitors in rat: a pharmacokinetic and pharmacodynamic modeling approach
Siphoning Blood Glucose: A Novel Therapy
T-1095, a Renal Na+-Glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats
The role of the kidneys in Glucose homeostasis: a new path towards normalizing glycaemia
Dapagliflozin, a selective SGLT2 inhibitor, improves Glucose homeostasis in normal and diabetic rats
Sodium Glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes
Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent Glucose co-transporter 2, in …
Targeting the kidney and Glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 Inhibition as a new option for treatment of type 2 …
Lowering plasma Glucose concentration by inhibiting Renal sodium–Glucose cotransport
Development of the sodium-Glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus
Physiologically based pharmacokinetic–pharmacodynamic modeling to predict concentrations and actions of sodium‐dependent Glucose transporter 2 inhibitor …
Novel SGLT 2 inhibitor: first‐in‐man studies of antisense compound is associated with unexpected Renal effects
The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta‐analysis
Associations of insulin levels and insulin resistance with urine Glucose excretion independent of blood Glucose in Chinese adults with prediabetes and newly …
Unmasking and aggravation of polycythemia vera by canagliflozin
Effects of Kaempferia parviflora Extract on Glucose Transporters in Human Renal Proximal Tubular Cells
Renal sodium-Glucose cotransporter Inhibition in the management of type 2 diabetes mellitus
Meet the SGLT2 inhibitors: these new type 2 diabetes medications block Glucose Reabsorption by the kidneys
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus
Sodium-Glucose co-transporters and their Inhibition: clinical physiology
The combinatorial effective approach of alpha-glucosidase inhibitor and Sodium-Glucose co-transporter 2 (SGLT-2)
Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes
SODIUM-Glucose TRANSPORTER 2 Inhibition–A POTENTIAL OPTION FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
SGLT2 inhibitors for type 2 diabetes
Risk of erythrocytosis during concomitant testosterone and SGLT2-inhibitor treatment: a warning from two clinical cases
SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?
Antidiabetic drugs and the kidney
Differentiating sodium-Glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus
Renal olfactory receptor 1393 contributes to the progression of type 2 diabetes in a diet-induced obesity model
Tofogliflozin: the road goes ever on
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
Distribution of Glucose transporters in Renal diseases
New potent antihyperglycemic agents in db/db mice: Synthesis and structure− activity relationship studies of (4-substituted benzyl)(trifluoromethyl) pyrazoles and …
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C‐MDG
Dapagliflozin attenuates Renal gluconeogenic enzyme expression in obese rats
Sodium–Glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes
A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-Glucose Cotransporter Type 2, in Healthy …
Sodium Glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus
A paradigm shift in diabetes therapy—dapagliflozin and other SGLT2 inhibitors
Canagliflozin, a sodium Glucose co-transporter 2 inhibitor, for the management of type 2 diabetes
Empagliflozin, a sodium Glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes
Mechanistic evaluation of the effect of sodium‐dependent Glucose transporter 2 inhibitors on delayed Glucose absorption in patients with type 2 diabetes mellitus …
The Role of the Kidney in Glucose Homeostasis
Natural products as lead compounds for sodium Glucose cotransporter (SGLT) inhibitors
Role of sodium-Glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
The Kidneys in Type 2 Diabetes Disturbed Glucose Homeostasis to Mechanism-Based Therapy
Sodium-Glucose cotransporter 2 Inhibition in type 1 diabetes: simultaneous Glucose lowering and Renal protection?
Kidney in diabetes: from organ damage target to therapeutic target
The Renal effects of SGLT2 inhibitors and a mini-review of the literature
Preventive effects of flavonoids on alloxan-induced diabetes mellitus in rats
Turning glucosuria into a therapy: Efficacy and safety with SGLT2 inhibitors
Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium–Glucose co‐transporter type 2, in Japanese subjects without and with …
Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium‐Glucose co‐transporter‐2, in people with type 2 diabetes mellitus
Potent sodium/Glucose cotransporter SGLT1/2 dual Inhibition improves glycemic control without marked gastrointestinal adaptation or colonic microbiota changes in …
DAPA-HF trial: dapagliflozin evolves from a Glucose-lowering agent to a therapy for heart failure
Dapagliflozin: A new drug for treatment of type 2 diabetes mellitus
Dapagliflozin for the treatment of type 2 diabetes
Improved diabetic syndrome in C57BL/KsJ‐db/db mice by oral administration of the Na+‐Glucose cotransporter inhibitor T‐1095
The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus
Sodium-Glucose co-transporter-2 drugs: are we sure they are useful only in the treatment of diabetes?
p63 and SOX2 dictate Glucose reliance and metabolic vulnerabilities in squamous cell carcinomas
Role of sodium/Glucose cotransporter Inhibition on a rat model of angiotensin II–dependent kidney damage
Dapagliflozin: a review on efficacy, clinical effectiveness and safety
Increased waist-to-hip ratio is associated with decreased urine Glucose excretion in adults with no history of diabetes
EMPA-REG OUTCOME: the nephrologist’s point of view
SGLT2 inhibitors: New medicines for addressing unmet needs in type 2 diabetes
Effect of Renal impairment on the pharmacokinetics and pharmacodynamics of tofogliflozin (a selective SGLT2 inhibitor) in patients with type 2 diabetes …
Structure-activity relationships of preventive effects of flavonoids in alloxan-induced diabetes mellitus in rats
Acute diuretic effect of aqueous extract of Retama raetam in normal rats
Sodium Glucose Co transporter 2 (SGLT2) Inhibitors: A New Sword for the Treatment of Type 2 Diabetes Mellitus
Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent Glucose cotransporter 2 and clinical candidate for the …
Impact of sodium–Glucose cotransporter 2 inhibitors on blood pressure
Renal gluconeogenesis in insulin resistance: A culprit for hyperglycemia in diabetes
Effect of sodium‐Glucose cotransporter 2 inhibitor, empagliflozin, and α‐glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
SGLT2 inhibitors in patients with type 2 diabetes and Renal disease: overview of current evidence
Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus
Sodium-Glucose Transporter 2 Inhibitors and Kidney
Use of Sodium–Glucose Cotransporter 2 (SGLT-2) Inhibitors Beyond Diabetes: On the Verge of a Paradigm Shift?
Ertugliflozin as a monotherapy for the treatment of type 2 diabetes
Pharmacogenetics of novel Glucose-lowering drugs
Pharmacokinetic and pharmacodynamic profiles of canagliflozin in Japanese patients with type 2 diabetes mellitus and moderate Renal impairment
Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
Short commentary on empagliflozin and its potential clinical impact
Caraway and caper: potential anti-hyperglycaemic plants in diabetic rats
The novel role of the kidney in diabetes management: Sodium-Glucose Co-Transporter 2 Inhibitors
Study of the hypoglycaemic activity of Lepidium sativum L. aqueous extract in normal and diabetic rats
Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-Glucose transporters (SGLTs) in mice
Long-term study of patients with type 2 diabetes and moderate Renal impairment shows that dapagliflozin reduces weight and blood pressure but does not …
Evolution of sodium Glucose co-transporter 2 inhibitors as anti-diabetic agents
Use of a sodium–Glucose cotransporter 2 inhibitor in a patient with chronic kidney disease
Assessing bladder cancer risk in type 2 diabetes clinical trials: the dapagliflozin drug development program as a ‘case study’
Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
Identification of phlorizin binding domains in sodium-Glucose cotransporter family: SGLT1 as a unique model system
Role of genetic variation in the human sodium–Glucose cotransporter 2 gene (SGLT2) in Glucose homeostasis
Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
Biopharmacological studies of the aqueous extract of Lepidium sativum seeds in alloxan-induced diabetes in rats
The sodium Glucose cotransporter type 2 inhibitor empagliflozin preserves β-cell mass and restores Glucose homeostasis in the male zucker diabetic fatty rat
Renal and cardiac implications of sodium Glucose cotransporter 2 (SGLT2) inhibitors: the state of the science
Improved Glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of …
SGLT2i: A novel approach to managing type 2 diabetes
Renal effects of sodium–Glucose cotransporter-2 inhibitors in patients with type 2 diabetes and Renal impairment
Sodium–Glucose Cotransporter 2 Inhibitor–Associated Prolonged Euglycemic Diabetic Ketoacidosis in Type 2 Diabetes: A Case Report and Literature Review
Patient considerations in the management of type 2 diabetes–critical appraisal of dapagliflozin
Clinical relevance of the selectivity of sodium-Glucose cotransporter-2 inhibitors.
Ipragliflozin, a sodium–Glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes
A Review on Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus
Protection of the kidney with sodium–Glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials
Canagliflozin, a sodium Glucose co-transporter 2 inhibitor, reduces post-meal Glucose excursion in patients with type 2 diabetes by a non-Renal mechanism …
SGLT Inhibition: a possible adjunctive treatment for type 1 diabetes
Sodium-Glucose co-transporter 2 inhibitors and the potential for cardiovascular risk reduction in patients with type 2 diabetes mellitus
Update review of the safety of sodium-Glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus
Sodium-coupled Glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application
Preclinical Species and Human Disposition of (1S, 2S, 3S, 4R, 5S)-5-[4-Chloro-3-(4-ethoxybenzyl) phenyl]-1-hydroxymethyl-6, 8-dioxabicyclo [3.2. 1] octane-2 …
Regulation of Renal brush-border Glucose transport in response to metabolic dysregulation
Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-Glucose cotransporter 2) Inhibition
Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, placebo-controlled, phase II study
Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects
Sodium-Glucose cotransporter 2 inhibitors: the pleiotropic mechanisms of actions
Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient presenting with acute pancreatitis
An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes
Type 2 diabetes: An updated overview
SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose
Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018)
Sugar absorption
Role of the kidney and SGLT-2 Inhibition in type 2 diabetes mellitus
SGLT2 inhibitors: not just another Glucose-lowering agent
Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus
The use of sodium-Glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations
Hypoglycemic activity of methanolic extract of Tectona grandis linn. Root in alloxan induced diabetic rats
Effect of the desert plant Retama raetam on glycaemia in normal and streptozotocin-induced diabetic rats
Pharmacokinetics and pharmacodynamics of henagliflozin, a sodium Glucose co-transporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus
Metformin supports the antidiabetic effect of a sodium Glucose cotransporter 2 inhibitor by suppressing endogenous Glucose production in diabetic mice
SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: An extensive review
High urinary Glucose is associated with improved Renal prognosis in patients with diabetes mellitus
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized …
SGLT2 inhibitors–a potential treatment for Alport syndrome
Comparative Analysis of the Preventive Effects of Canagliflozin, a Sodium-Glucose Co-Transporter-2 Inhibitor, on Body Weight Gain Between Oral Gavage …
Development of sodium-dependent Glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics
Lepidium species as antidiabetic herbal medicines
Pathophysiology of Type 2 Diabetes
The effect of saffron (Crocus sativus L.) and its ingredients on the management of diabetes mellitus and dislipidemia
Luseogliflozin: first global approval
A mechanistic investigation into the acute effects of apple polyphenols on carbohydrate digestion and absorption
The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes
The potential role of sodium Glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
Glucose lowering efficacy and pleiotropic effects of sodium-Glucose cotransporter 2 inhibitors
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Diabetes Mellitus, Obesity and Phytotherapy
Combined antidiabetic benefits of exenatide and dapagliflozin in diabetic mice
Ethnobotanical Survey of Medicinal Plants Used by Traditional Healers to Treat Diabetes in the Taza Region of Morocco
The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin
Initial experience of SGLT2 inhibitor use in type 2 diabetes
Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes
Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the Renal …
Pharmacologic management of type 2 diabetes mellitus: available therapies
Hypoglycaemic effect of Triticum repens P. Beauv. in normal and diabetic rats
Effects of diuretics on sodium-dependent Glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome
Mechanism and efficacy of new anti-diabetic medications
Cardiovascular effects of sodium Glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus
Chronic treatment with dapagliflozin protects against mitochondrial dysfunction in the liver of C57BL/6NCrl mice with high-fat diet/streptozotocin-induced diabetes …
Inhibitors of sodium-Glucose linked transporter 2-A new class antidiabetic drugs used for the treatment of diabetes mellitus type 2
Antinociceptive activity of aqueous extract of Lepidium sativum L. in mice
Combination therapy for type 2 diabetes: dapagliflozin plus metformin
A Novel Double-Tracer Technique to Characterize Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]Tofogliflozin After Oral Administration and Concomitant …
Use of canagliflozin in combination with and compared to incretin-based therapies in type 2 diabetes
Comparisons of weight changes between sodium‐Glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment in type 2 diabetes …
Diabetes and medicinal plants-A review
Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats
Role of insulin in the abnormal glucagon secretory response to hypoglycemia in type 1 diabetes
The new direction in medical
Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes
Novel avenues for treating diabetic nephropathy: new investigational drugs
Effects of phlorizin on vascular complications in diabetes db/db mice
A review: antidiabetic medicinal plants used for diabetes mellitus
Apple polyphenol-rich drinks dose-dependently decrease early-phase postprandial Glucose concentrations following a high-carbohydrate meal: a randomized …
Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study
ANTI-HYPERGLYCAEMIC EFFECT OF SOME UNANI FORMULATIONS IN THE MANAGEMENT OF DIABETES MELLITUS TYPE 2
Drug off-target effects predicted using structural analysis in the context of a metabolic network model
Effects of Zanthoxylum zanthoxyloides leaves on blood Glucose, lipid profile and some liver enzymes in alloxan induced diabetic rats
Early administration of empagliflozin preserved heart function in cardioRenal syndrome in rat
The sodium Glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin lowers blood pressure independent of weight or HbA1c changes
Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition
Efficacy and safety of sodium‐Glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis
Energy loss via urine and faeces–a combustive analysis in diabetic rats and the impact of antidiabetic treatment on body weight
Sodium Glucose co-transporter-2 inhibitor: benefits beyond glycemic control
Ketone bodies for kidney injury and disease
Repurposing drugs to target the diabetes epidemic
A systematic Review on Antidiabetic medicinal Plants
Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight …
The new direction in medical management of chronic heart failure with reduced ejection fraction
Role of nutrient transporters in lifestyle-related diseases
SGLT-2 inhibitors-hope or hype?-an updated review
Biology of human sodium Glucose transporters
Canagliflozin, a novel SGLT2 inhibitor for treatment of type 2 diabetes
New-Onset Diabetes after Kidney Transplantation: Diagnosis, Risk Factors, and Management
The role of glucagon in the acute therapeutic effects of SGLT2 Inhibition
New pharmacological approaches to diabetes management
Diuretic activity of methanolic extract of Physalis minima leaves
New therapeutic strategies for type 2 diabetes CME
Dandelion: Phytochemistry and clinical potential
The emerging role of adjunctive noninsulin antihyperglycemic therapy in the management of type 1 diabetes
Contribution of hyperglycemia on diabetic complications in obese type 2 diabetic SDT fatty rats: effects of SGLT inhibitor phlorizin
Resveratrol improves glycemic control in insulin-treated diabetic rats: participation of the hepatic territory
Glucose lowering treatment modalities of type 2 diabetes mellitus
www. OpenCME. org/course/where-do-sglt2-inhibitors-fit-spectrum-of-treatment-of-t2dm
A systematic review on effect of canagliflozin in special population
Selected biologically active substances and healing properties of dandelion (Taraxacum officinale)
Hypoglycaemic activity and nephro-protectective effect of Bauhinia rufescens in alloxan-induced diabetic rats
Lipid Accumulation Product Combined With Urine Glucose Excretion Improves the Efficiency of Diabetes Screening in Chinese Adults
The Role of Adipose Tissue in Diabetic Kidney Disease
Antihyperglycemic Studies on the Leaf Extract and Active Fractions of Newbouldia laevis (Bignoniaceae)
Challenges for the treatment of diabetes mellitus
Plants having potential antidiabetic activity: a review
Intraoperative Diagnosis of Sodium-Glucose Cotransporter 2 Inhibitor–Associated Euglycemic Diabetic Ketoacidosis: A Case Report
Treatment approach to type 2 diabetes: Past, present and future
OP8-3: Adaptive changes of transposed ileum and their potential roles in the metabolic benefits of bariatric surgery
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
The molecular mechanisms of pancreatic β-cell glucotoxicity: recent findings and future research directions
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
The effect of dapagliflozin on clinical, metabolic and Renal parameters in type 2 diabetic patient in University of Malaya Medical Centre: A single centre experience/Ho …
Antidiabetics Review on Natural Products
An expert update on novel therapeutic targets for hyperphosphatemia in chronic kidney disease: preclinical and clinical innovations
Potential role of yoga in management of the ominous octet: Adding a new facet to type 2 diabetes management and prevention
Postprandial macrophage-derived IL-1β stimulates insulin, and both synergistically promote Glucose disposal and inflammation
Effect of saffron (Crocus sativus L.) on lipid profile, glycemic indices and antioxidant status among overweight/obese prediabetic individuals: A double-blinded …
The metabolic model of heart failure: the role of sodium Glucose co-transporter-2 (SGLT-2) Inhibition
Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload
Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution
Bioequivalence of fixed‐dose combinations of dapagliflozin and metformin with single‐component tablets in healthy subjects and the effect of food on bioavailability
Metabolomic and microarray analyses of adipose tissue of dapagliflozin-treated mice, and effects of 3-hydroxybutyrate on induction of adiponectin in …
PE-4: Effects of polydextrose on glycemic and insulinemic responses in healthy normal weight and overweight women when consumed during a breakfast meal
Assessing the kidney function parameters glomerular filtration rate and effective Renal plasma flow with dynamic FDG-PET/MRI in healthy subjects
Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study
The therapeutic journey of benzimidazoles: a review
Sodium-Glucose cotransporter 2 inhibitors and cardiovascular outcomes
Glucose transport at the Renal brush border membrane: GLUT2 and the involvement of PKC-βI
Can we trust the positivity of semi-quantitative Glucose measurement in the urine?
Can we trust the positivity of semi-quantitative Glucose measurement in the urine?
Our Practice
Asian Journal of Phytomedicine and Clinical Research
Identification of key nodes of type 2 diabetes mellitus protein interactome and study of their interactions with phloridzin
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review …
Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study
Novel therapeutic agents for the treatment of diabetic kidney disease
Pharmacognosy, phytochemistry, pharmacology and clinical applications of Taraxacum officinale
The Future of Diabetes Therapy
Review of empagliflozin monotherapy for previously untreated patients with type 2 diabetes mellitus: Comparison with sitagliptin: Original article: Roden M, Weng J …
Evaluation of Comparative Efficacy and Pleiotrophy of the Available Three SGLT2 Inhibitors in Type 2 DM Subjects
Anti-ulcerogenic effects and anti-oxidative properties of Ceiba pentandra leaves on alloxan-induced diabetic rats
A new analytical method for determination of dolutegravir and rilpivirine in pharmaceutical formulations by RP-HPLC method
Arterial pressure lability is improved by sodium-Glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats
Pancreatic islet regeneration and some liver biochemical parameters of leaf extracts of Vitex doniana in normal and streptozotocin–induced diabetic albino …
Our Practice Newsletter: By Pharmacists For Pharmacists, issue 3
Diabetes mellitus and use of medicinal plants for its treatment
Present and future challenges in Type 2 diabetes
Dapagliflozin, A Selective SGLT2 Inhibitor for Treatment of Diabetes
Antidiabetic attributes of desert and steppic plants: a review
Diabetes mellitus and hypertension: a dual threat
Chronopharmacology of dapagliflozin-induced antihyperglycemic effects in C57BL/6J mice
Therapeutic role of fibroblast growth factor 21 (FGF21) in the amelioration of chronic diseases
Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET …
Drug utilization patterns in patients with diabetes initiating sodium Glucose co-transporter-2 inhibitors (SGLT2i) in Japan: a multi-database study (2014–2017)
Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study
Tripeptides of RS1 (RSC1A1) inhibit a monosaccharide-dependent exocytotic pathway of Na+-D-Glucose cotransporter SGLT1 with high affinity
Hormone‐substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active‐controlled DURATION‐8 study
Some selected medicinal plants with antidiabetic potentials
Pharmacologic treatment options for type 1 diabetes: what’s new?
Contribution to the study of medicinal plants used in the treatment of diabetes, obesity and hypertension in Tafilalet region (Morocco)
The physiological effects of dandelion (Taraxacum officinale) in type 2 diabetes
Diabetes and cardiovascular risk in Renal transplant patients
Addition of dipeptidyl peptidase‐4 inhibitors to insulin treatment in type 2 diabetes patients: A meta‐analysis
Empagliflozin for type 2 diabetes mellitus: an overview of phase 3 clinical trials
OP8-2: The effect of bariatric surgery on fatty acid uptake and associated gene expression in abdominal subcutaneous adipose tissue of morbidly obese women
Repurposing existing drugs for COVID-19: an endocrinology perspective
SGLT-2 Inhibition in the kidney: changing paradigms in the treatment of type 2 diabetes mellitus
Pharmacological profile of tofogliflozin, a novel SGLT2 inhibitor, in preclinical studies
Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose …
Approach to diabetes management in patients with CVD
Implications of the CANVAS Study in Reducing Cardiovascular Outcomes
Pathophysiological Association between Diabetes Mellitus and Endothelial Dysfunction
The Ameliorative Potential of Saffron Against the Histological and Immunohistochemical Changes in Kidney of Albino Mice Due to Streptozotocin-Induced Diabetes …
Empagliflozin therapy and insulin resistance-associated disorders: effects and promises beyond a diabetic state
PE-1: Comparing the efficacy of different health education tools for improving blood Glucose control in patients with type 2 diabetes
PE-2: Assessment of universal healthcare coverage of diabetes prevalence in a north India district: a rapid survey in urban and rural areas
Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/Glucose‐cotransporter 2 …
Hypoglycaemic and Hypolipidemic Effects of Black Brand of Lipton Tea (Camellia sinensis) on Normal Male Albino Rats
Anti sense and sensibility: Renal and skin effects of (antisense) oligonucleotides
β-Cell plasticity
Hypoglycemic Activity of Extract Leaf and Root Plant of Jombang (Taraxacum Officinale) in Alloxan-Induced Diabetic Wistar Male Rats
Benzimidazole: Journey from Single Targeting to Multitargeting Molecule
Gut mechanisms linking intestinal sweet sensing to glycemic control
Hypoglycemic Activity of Extract Leaf and Root Plant of Jombang (Taraxacum Officinale) in Alloxan-Induced Diabetic Wistar Male Rats
Evaluation of antioxidant, hypoglycemic and hypolipidemic effects of the phytoconstituents of Cinnamomum tamala in rats
OP8-4: Plasmalogens regulate macrophage polarization and protect against adipose tissue inflammation in high fat diet-fed mice
PE-3: Artificial sweeteners content in sugar free products and public attitude of use in Muscat, Oman
Silica-coated magnetic nanoparticles induce Glucose metabolic dysfunction in vitro via the generation of reactive oxygen species
The relationship between peripheral Glucose utilisation and insulin sensitivity in the regulation of hepatic Glucose production: studies in normal and alloxan‐diabetic …
Role of Retama Raetam on Gentamicin-Induced Acute Kidney Injury in Experimental Rat Model
Nonlinear ODE mathematical analysis of the insulin-Glucose model in the presence of a condition in glycemia function H (G).
A review: Medicinal plants and its impact on diabetes
Antidiabetic, antioxidant and anti inflammatory properties of water and n-butanol soluble extracts from Saharian Anvillea radiata in high-fat-diet fed mice
Focused Ultrasound Modulation of Hepatic Neural Plexus Restores Glucose Homeostasis in Diabetes
Application of clinical judgment and guidelines to achieving glycemic goals in type 2 diabetes: focus on pharmacologic therapy
Hypoglycemic and hypolipidemic effects of ethyl acetate leaf extract of Vitex simplicifolia in alloxan induced diabetic wister rats
Role of Retama Raetam on Gentamicin-Induced Acute Kidney Injury in Experimental Rat Model Medhat M. Menshawy1 Abdel Razik H. Farrag 2, Sayed A. El …
Role of Canagliflozin on function of CD34+ ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
The Effect of Empagliflozin on Left Ventricular Mass and Myocardial Extracellular Volume in Patients with Type 2 Diabetes and Cardiovascular Disease
Cress seed (lepidium sativum) role in the healthy processed spread cheese and its anti-diabetic activity
Possible ways to improve postprandial Glucose control in type 1 diabetes
New therapeutic agents for glycemic control in diabetes mellitus
Drug Utilization Patterns in Patients with Diabetes Initiating Sodium Glucose Co-Transporter-2 Inhibitors (SGLT2i) in Japan: A Multi-Database Study (2014–2017)
Role of some Egyptian medicinal plants against liver and kidney toxicity induced by cadmium chloride
A new analytical method for determination of ledipasvir and sofosbuvir in pharmaceutical formulations by HPLC method
Evaluation of medicinal plants used to diabetes treatment
Glucose-lowering effects and safety of DS-8500a, a G protein-coupled receptor 119 agonist, in Japanese patients with type 2 diabetes: results of a …
Skeletal muscle basal AMP-activated protein kinase activity is chronically elevated in alloxan-diabetic dogs: impact of exercise
HERBAL INTERVENTIONS IN MANAGING DIABETES MELLITUS: A REVIEW
Options for empagliflozin in combination therapy in type 2 diabetes mellitus
Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial
LEELA MADHURI POLA1
The effects of plant-derived oleanolic acid on kidney function in male Sprague-Dawley rats and, in cell lines of the kidney and liver.
Novel research strategies of benzimidazole derivatives: a review
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study
Type 2 diabetes mellitus and the elderly: an update on drugs used to treat glycaemia
Combined effect of canagliflozin and exercise training on high-fat diet-fed mice
Natural Products Derived from the Mediterranean Diet with Antidiabetic Activity: from Insulin Mimetic Hypoglycemic to Nutriepigenetic Modulator Compounds
Cardiovascular risks and benefits with oral drugs for Type 2 diabetes mellitus
Prevailing hyperglycemia is critical in the regulation of Glucose metabolism during exercise in poorly controlled alloxan-diabetic dogs
Factors influencing seed germination of the pastoral plant Retama raetam subsp. bovei (Fabaceae): interactive effects of fruit morphology, salinity, and osmotic stress
on Pharmacometrics 2014 (ACoP5)
Polyphenols of apples and their potential health benefits
Endothelial Dysfunction in Diabetes: An Update on Mechanisms and Therapeutic Targets
Studies on kidney pathophysiological analyses in SDT fatty rat, a novel obese diabetic model
19 Interview| Prof. dr. U. Beuers
Impact of an exercise program on acylcarnitines in obesity: a prospective controlled study.
Evaluation of the stability of exenatide in aqueous solutions
Clinical Trial Number NCT02635386
Medicinal plants used for the treatment of diabetes and its long-term complications
Should the recommendation of the American Association of Clinical Endocrinologists for a hemoglobin A1c target of 6.5% be modified? A critical reappraisal of recent …
Fruit and vegetable waste management: Conventional and emerging approaches
Diabetes mellitus and cardiovascular disease in the elderly
CONTINUOUS Glucose MONITORING 1-OR
NURDIANA BINTI SAMSULRIZAL
The in vitro and in vivo anti-oxidative and anti-diabetic effects of some African medicinal plants and the identification of the bioactive compounds.
In-depth Studies of the Antioxidant Profile of Aegle marmelos and Its Impact on Healthy and Type II Diabetes Mellitus Subjects
Mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Effective diet against o minous octet
Investigation of CPR knowledge dependence on driving experience and participation in first aid training
The development and health of premature infants born before the 30th pregnancy week at the age of six
Evaluation of mechanical power caused by different mechanical lung ventilation methods
Neurological complications of pandemic A (H1N1) 2009PDM, post-pandemic (H1N1) V, and seasonal influenza A
INSULIN TREATMENT IN TYPE 2 DIABETES
General anesthesia from patients perspective: what myths are most common?
Roots/Health Benefits of Apples

Inhibition Of Renal Glucose Reabsorption

Anti Glycation Agents

Sglt2 Inhibitors

Increases Spermatogenesis

support@interstellarblends.com